Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBM-IC2
- Development stage
- Preclinical
- Lead developer
- Moffitt Cancer Center
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
GBM-IC2 is a targeting peptide identified through in vivo phage display biopanning that specifically binds to N-cadherin (CDH2) on glioma stem cells (GSCs). Developed by researchers at the Moffitt Cancer Center, the peptide was selected for its ability to bind specifically to GSCs in vitro and glioblastoma (GBM) tissue in vivo. N-cadherin is a surface receptor associated with self-renewal and tumor recapitulation in glioma, making it a potential marker for treatment-resistant cell populations. GBM-IC2 is being investigated as a vehicle for targeted therapeutic delivery or as a diagnostic tool for identifying aggressive cell populations within brain tumors.
02
Targets
CDH2 (N-cadherin)
Beyond the preview
Go deeper on GBM-IC2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBM-IC2.